The Vytorin Controversy and Surrogate Markers
> Monday, April-14-2008
The big news at the American College of Cardiology annual meeting in Chicago March 29-April 1 was the controversy caused by the ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) trial result, essentially ending a 2 billion dollar annual market overnight.
